EUVIMEDEUVIMED entdecken
Crossref

Abstract 4232: The Poly(ADP-ribose) Polymerase 1 Inhibitor Olaparib Ameliorates Cediranib-Induced Cardiotoxicity

Jie Ma, Ying dong Wang, Xin Ma, Chuyan Feng, Jing Yu

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.4232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Jie Ma und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Cediranib, a potent pan-VEGFR tyrosine kinase inhibitor, has shown antitumor activity in several malignancies and is clinically combined with the PARP inhibitor olaparib in selected oncological settings. However, cediranib-associated cardiovascular toxicity, including hypertension, left ventricular dysfunction and heart failure, remains an important limitation of VEGFR-targeted therapy. Although olaparib is primarily used as an antitumor agent, whether it modulates cediranib-induced cardiac injury has not been fully defined. We hypothesized that cediranib-induced cardiotoxicity is associated with oxidative stress, PARP1/PARylation activation and PI3K/AKT signaling dysregulation, and that olaparib may attenuate these alterations in preclinical models.

Methods

Cediranib-induced cardiotoxicity was modeled in C57BL/6 mice (5-week oral cediranib ± olaparib) and in H9c2 cardiac-derived cells. Cardiac function was assessed by echocardiography; myocardial injury was evaluated by histology and circulating hs-cTnT/NT-proBNP. Oxidative stress, DNA damage, PARP1/PARylation, and PI3K/AKT signaling were profiled by immunohistochemistry, immunofluorescence, flow cytometry, and Western blotting. Quantitative proteomic analysis was performed to identify cediranib-associated molecular pathways in myocardial tissue.

Results

Cediranib reduced LVEF and fractional shortening, increased plasma hs-cTnT and NT-proBNP levels, disrupted myocardial architecture, increased OGG1 expression, reduced SOD1 expression, and enhanced PARP1 expression and global PARylation. Quantitative proteomic profiling identified 265 differentially expressed proteins in cediranib-treated hearts, with enrichment of pathways related to focal adhesion, oxidative stress response and PI3K/AKT signaling. Western blot analysis confirmed that cediranib reduced p-PI3K/PI3K and p-AKT/AKT ratios in myocardial tissue. Co-administration of olaparib improved cardiac systolic function, attenuated myocardial injury biomarkers, reduced oxidative stress-associated alterations, suppressed PARP1/PARylation activation, and partially restored PI3K/AKT signaling in vivo and in H9c2 cardiac-derived cells.

Conclusions

This study suggests that PARP1/PARylation activation is associated with cediranib-induced cardiac injury and that olaparib attenuates this toxicity in preclinical models, potentially through modulation of oxidative stress and PI3K/AKT signaling.

Zitieren

APA

Ma, J., Wang, Y. D., Ma, X., Feng, C., & Yu, J. (2026). Abstract 4232: The Poly(ADP-ribose) Polymerase 1 Inhibitor Olaparib Ameliorates Cediranib-Induced Cardiotoxicity. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.4232

Vancouver

Ma J, Wang YD, Ma X, Feng C, Yu J. Abstract 4232: The Poly(ADP-ribose) Polymerase 1 Inhibitor Olaparib Ameliorates Cediranib-Induced Cardiotoxicity. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.4232

BibTeX
@article{Ma2026,
  author = {Ma, Jie and Wang, Ying dong and Ma, Xin and Feng, Chuyan and Yu, Jing},
  title = {Abstract 4232: The Poly(ADP-ribose) Polymerase 1 Inhibitor Olaparib Ameliorates Cediranib-Induced Cardiotoxicity},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.4232}
}
Kostenlos starten →